An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Glaukos Corporation (NYSE: GKOS), an innovative company specializing in ophthalmic medical technology, is set to release its first quarter 2023 financial results after the market closes on May 3, 2023. Following the release, management will conduct a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. Interested parties can access the webcast via Glaukos' investor relations website. The company is recognized for developing Micro-Invasive Glaucoma Surgery (MIGS) devices and aims to enhance treatment options for glaucoma, corneal disorders, and retinal diseases through continuous innovation.
Positive
None.
Negative
None.
Conference Call and Webcast Scheduled for 1:30 p.m. PT
ALISO VIEJO, Calif.--(BUSINESS WIRE)--
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on May 3, 2023.
A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.
Chris Lewis Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
When will Glaukos Corporation release its Q1 2023 financial results?
Glaukos Corporation will release its Q1 2023 financial results after the market closes on May 3, 2023.
What time is Glaukos Corporation's conference call for Q1 2023 results?
The conference call for Glaukos Corporation's Q1 2023 results is scheduled for 1:30 p.m. PT (4:30 p.m. ET) on May 3, 2023.
How can I access the webcast of Glaukos Corporation's conference call?
You can access the webcast of Glaukos Corporation's conference call through their investor relations website.
What is Glaukos Corporation known for?
Glaukos Corporation is known for developing innovative therapies, specifically Micro-Invasive Glaucoma Surgery (MIGS) devices for treating glaucoma and other ocular conditions.
